Seven different digoxin immunoassay kits showed cross reactivity with an endogenous digoxin-like immunoreactive substance consistently present in serum of neonates, whether premature or full-term. The degree of interference, in decreasing order was: NML> New England Nuclear> BioRad > Clinical Assays > Becton Dickinson > Serono > Syva (EMIT). More recentlypurchased NML kits showed less sensitivity to the substance, evidently reflecting lot-to-lot differences in antibody. A single baseline determinationof the substance before digoxin is administered inadequately compensates for this interference, because the interferent concentrations can differ from day to day, with evidence that it may be most concentrated on the fourth to sixth postnatal day. Its concentration in the serum of neonates is unrelated to the concentrationof dehydroepiandrostenedionesulfate, an indicatorof fetal adrenal-corticalactivity.
to the concentrationof dehydroepiandrostenedionesulfate, an indicatorof fetal adrenal-corticalactivity.
We recently reported the finding of a digoxin-like immunoreactive substance (DUS) in premature and full-term infants not receiving digoxin therapy (1). Initially we saw no significant correlation between the concentration of DLIS and the babies' weight, medication, or Apgar score. No common clinical condition appeared to be associated with increased DLIS concentrations. Full-term infants older than two months did not appear to have high concentrations of DUS (<0.2 g/L) but some premature infants might have relatively higher, and more persistently high, concentrations. When we assayed with a commercial radioimmunoassay (RIA) kit for digoxin (NML Laboratories Inc., Dallas, TX 75247) in serum and cord blood from 25 premature and full-term infants (age range 0-146 days), the values for serum digoxin ranged from 0.3 to 4.1 g/L (mean ± SD, 1.4 ± 0.8). When we analyzed these same specimens with another commonly used RIA kit (Clinical Assays, Cambridge, MA 02139), values obtained were about half as great.
These results motivated us to investigate the relative cross reactivity of DLIS with five additional iminunoassay kits, and to look at antibody lot-to-lot variability with kits. We also sequentially measured DLIS, to determine withinday and day-to-day changes in its concentration.
We concurrently measured dehydroepiandrostenedione sulfate (DHEA-S04), a major product of the fetal adrenal cortex, to determine the relationship, if any, between fetal adrenalcortical activity and DLIS. 
Materials and Methods
We stored at 4#{176}C the excess from each of about 300 serum specimens from premature and full-term neonates in the intensive care nursery, none of whom was being treated with digoxin. We assayed all of these specimens with the NML RIA kit, to determine interference by DLIS with the digoxin assay.
The respective samples were then combined according to the value obtained for DUS (expressed as apparent digoxin), to give sufficient sample volumes for analysis with other immunoassay kits for digoxim. We determined within-day, within-individual variation in DLIS by analysis of two samples, drawn at two times during a 24-h period, from each of 63 babies from the intensive care nursery.
We compared day-to-day variation in DLIS and DHEA-SO4 in four premature babies from birth to the 14th postnatal day, DHEA-SO4 being assayed with an RIA kit from Pantex, Santa Monica, CA 90404. Figure 1 shows the values for DLIS as measured with six different immunoassay kits as a function of those obtained with the NML digoxin method in digoxin-free samples. The statistical parameters of the correlation data are summarized in Table 1 Figure 2 shows the comparison of DLIS as determined by lot DB-157 and a newer lot (DB-163), obtained from a different rabbit than lot DB-157. The more recent lots of antisera from NML are less than half as sensitive to this endogenous interference.
Results
We analyzed 63 sample pairs taken at separate times on the same day from different babies in the intensive care unit to assess individual and within-day variation of DLIS. The mean of this population was 1.5 gfL (range 0.6-4.4 gfL). The standard deviation for intra-individual intraday variation was ± 0.14 tg/L, which is not significantly different from the analytical precision of duplicate analyses of ± 0.10 The day-to-day variation in DLIS for four premature babies is shown in Figure 3 . DLIS peaked at four to six days after birth in these four cases and then gradually declined. Figure 3 also shows that the concentrations of DHEA-S04, which reflects fetal adrenal-cortical activity, apparently bear no relationship to the DLIS concentrations.
Discussion
In a continuation of our previous studies (1), we have now shown that DLIS cross reacts in several other commercial digoxin imniunoassay methods. All seven kits checked showed some degree of cross reactivity with this interfering A change in the source of antiserum (i.e., from rabbit to rabbit) was accompanied by a marked change in the cross reactivity of the NML kit to DLIS.
The magnitude of the DUS in some infants is sufficient to compromise the usefulness of a measured value for digoxin DUE is relatively small, but between-day variation may be quite large in the first two postnatal weeks; therefore, a single baseline pre-digitalization measurement is inadequate to predict DLIS concentrations over the following days.
DLIS content appears to peak four to six days after birth, with the highest concentrations occurring in the lowestbirth-weight babies (see Figure 3) . No firm conclusion can be drawn from the present study because of the small number of subjects. We are currently investigating the clinical significance of these changes in a larger population of neonates.
Although we had speculated (1) that DUE might be coming from the fetal adrenal cortex because involution of the fetal adrenal cortex coincided with peak concentrations of DUS and because the structure of digoxin is similar to that of the adrenal steroids, our latest results show that there is no relationship between DHEA-SO4 and DUS concentrations in the neonate. The nature and significance of DUE in the present study remain to be determined. Natriuretic hormone (2) , math-CLIN. CHEM. 29/11, 1974-1977(1983) uretic factor (3), cardiotropic factor (4) and (or) some nonspecific substance that interferes with routine measurements of serum digoxin in infants are possibilities that will have to be investigated in future studies.
